Oh, those wacky metals. One day, everybody is worried about strikes and shortages, and the next day, people start noticing the gap between the current trading prices of many metals and their marginal production costs. And that's just the market perception -- metal recycler Metal Management
Volatility or no, this was still a decent fiscal fourth quarter for the company. Revenue was down 6%, but the company did ship a pretty solid volume of non-ferrous scrap. Margins looked good, and the company posted operating income growth of roughly 23% and EBITDA growth of 20%.
As I said, the price environment is still pretty rocky. Prices for ferrous scrap dropped about 14% from last year, but non-ferrous prices rose 22%. The company didn't go into detail on that latter point, but my guess would be that the high market value of metals like copper and zinc would have been a big help. Despite the pricing environment, Metal Management did make the most of the flexibility in its operations, cutting back on exports to take advantage of a relatively better local market.
As for what the future holds for scrap-metal pricing, I have no idea. Big users of scrap like Nucor
There's no question that you can make a lot of money on stocks like Metal Management -- or competitors like Commercial Metals
For more heavy metal Foolishness:
Our newsletter services can help you build a solid framework for your portfolio. You can try out any of them free for 30 days.
Fool contributor Stephen Simpson has no financial interest in any stocks mentioned (that means he's neither long nor short the shares).
More from The Motley Fool
ADT IPO: What Investors Need to Know
The security services company not only wants to guard your home and property, it wants to sell you some of its new stock, too.
Netflix Earnings: What to Watch
Can Netflix convince investors it can maintain strong momentum in 2018?
What Happened in the Stock Market Today
On a day stocks bounced up and down, shares of Energizer Holdings rose on acquisition news, and Merck reported positive results in a lung cancer trial.